- Fosun Pharma posted a net income of 1.22 billion yuan for the first half of 2024.
- Total Research and Development (R&D) expenses for the period were 1.86 billion yuan.
- Earnings Per Share (EPS) stood at 46 RMB cents.
- Analysts have given the company 6 buy ratings, 3 hold ratings, and no sell ratings.
A look at Shanghai Fosun Pharmaceutical (Group) Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a pharmaceutical company with a diverse portfolio, has garnered positive Smartkarma Smart Scores. With a solid Value score of 4, the company is seen as undervalued by analysts, potentially offering good investment opportunities. Additionally, its Dividend score of 4 indicates a strong track record of paying dividends to shareholders, appealing to income-oriented investors.
While the Growth and Resilience scores are slightly lower at 3, Shanghai Fosun Pharmaceutical (Group) shines in Momentum with a score of 5, suggesting strong market performance and investor interest. Overall, the company’s outlook seems promising, balancing value, dividends, and momentum in the pharmaceutical sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
